Connect with us

MEDICAL

Omadacycline is noninferior to moxifloxacin in treating community acquired bacterial pneumonia

Liberty Peters

Published

on

1. Intensive care unit (ICU) hospitalized adults with community acquired bacterial pneumonia had comparable clinical responses when taking antibiotic courses of omadacycline, a new trial antibiotic, versus moxifloxacin.

2. The observed safety profile of omadacycline was noted to be consistent with other known tetracyclines.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Community acquired pneumonia is a common cause of hospitalization; it also has increasing rates of resistance to traditional antibiotics necessitating research for new antibiotic agents. Omadacycline is a new antibiotic from the tetracycline class, and it has in vitro activity against known pathogens commonly implicated in community acquired bacterial pneumonia. In this current study, researchers assessed the efficacy and safety profile of omadacycline versus a traditional antibiotic, moxifloxacin, among adult ICU patients with community acquired pneumonia. Overall, omadacycline was noninferior to moxifloxacin when early clinical response and overall clinical response rates were assessed, based on patient survival and symptoms. Researchers also noted that the safety profile of omadacycline was comparable to other tetracyclines.

Though results may not be generalizable to a larger patient population, this study still highlights that clinicians may be able to consider newer antibiotic agents to treat resistant bacterial community acquired pneumonia. A notable strength includes thorough microbial assessment which determined the causative pathogen in 50% of cases. This may also present a limitation as real world rates of pathogen identification are dramatically lower.

Click to read the study in NEJM

Relevant Reading: New antibiotics for community-acquired pneumonia

In-Depth [randomized controlled trial]: This multicenter, phase III, double-blind, noninferiority randomized control trial enrolled 774 participants across 86 sites between 2015 to 2017. Patients were randomized in a 1:1 ratio to either receive 7 to 14 days of 100 mg omadacycline or 400 mg moxifloxacin (both initially administered intravenously with option to switch to oral formulation after 3 days). The primary outcome of this study was evidence of an early clinical response, assessed between 72 to 120 hours after the initial dose of antibiotics were given. Investigators assessed for symptoms of community acquired pneumonia (cough, sputum production, pleuritic chest pain, dyspnea) and measured if there was improvement in symptoms to determine if there was adequate early clinical response. Secondary endpoints included investigator-assessed clinical response at the post-treatment evaluation period (5 to 10 days after the last dose of antibiotic was given) and evidence of adverse events. Results showed that the most frequently encountered identified pathogens that caused community acquired bacterial pneumonia were Mycoplasma pneumoniae (33%). Streptococcus pneunomiae (20%), Legionella pneumophila (19%), Chlamydia pneumoniae (15%) and Haemophilus influenza (12%). Omadacycline was shown to be noninferior to moxifloxacin when early clinical response rates were measured among an intention-to-treat population (81.1% vs 82.7% respectively; -1.6 percentage difference; 95% confidence interval [CI], -7.1 to 3.8). Clinical response rates were also similar when assessed at the end of the treatment course (87.6% vs 85.1%; 2.5 percentage difference; 95% CI, -2.4 to 7.4). Adverse events occurred in 41.1% of patients in the omadacycline group and 48.5% of patients in the moxifloxacin group. The most common adverse events included gastrointestinal events, such as constipation vomiting and nausea. Severe adverse events occurred in 6.0% of omadacycline patients and in 6.7% of moxifloxacin patients, including twelve total deaths (8 in omadacycline group and 4 in the moxifloxacin group).

©2019 HPSN. All rights reserved. No works may be reproduced without expressed written consent from HPSN. Join our world acclaimed Facebook group here. No article should be construed as medical advice and is not intended as such by the authors or by HPSN

Member and content contributor for the Human Parasites Support Network. Also co-hosts on the HPSN talk show. Survivor and victim of parasitic infections.

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Medical News

MEDICAL10 hours ago

Quick Take: Association of Systemic Antibiotic Treatment of Acne With Skin Microbiota Characteristics

Systemic antibiotics are commonly used in the treatment of acne. However, the impact of their use on the complete bacterial...

MEDICAL10 hours ago

New herpes zoster vaccine predicted to be more cost effective than predecessor  

1. In a computational model, the new “recombinant zoster vaccine” (RZV) was predicted to be most cost-effective than the previous...

MEDICAL22 hours ago

Chinese population study shows high prevalence of elevated cardiovascular disease risk and low utilization of pharmacotherapy

1. In this national screening project, around 10% of middle-aged Chinese subjects were found to be at “high risk” for...

MEDICAL1 day ago

The KATHERINE trial: trastuzumab emtansine more effective than trastuzumab alone for treating residual HER2-positive breast cancer

1. Patients with residual human epidermal growth factor receptor 2 (HER2)-positive breast cancer after chemotherapy and HER2 targeted therapy had...

MEDICAL2 days ago

Peripheral perfusion-targeted resuscitation does not lower mortality in septic shock patients

1. In this randomized controlled trial, there was no difference in 28-day mortality in patients with early septic shock between...

MEDICAL2 days ago

The CLEAR trial: decolonization routine associated with lower infection risk among MRSA carrier patients

1. Hospitalized patients with known MRSA colonization randomized to undergo a decolonization routine were found to have lower risks of...

MEDICAL3 days ago

Addition of IV acetaminophen with propofol or dexmedetomidine reduces risk of post-operative delirium in older patients undergoing cardiac surgery

1. In this randomized controlled trial, post-operative scheduled intravenous (IV) acetaminophen combined with propofol or dexmedetomidine reduced risk of post-operative...

MEDICAL3 days ago

Nurse-led psychological intervention does not reduce PTSD symptoms in ICU patients

1. In this randomized clinical trial, nurse-led psychological interventions did not reduce PTSD risk at 6 months compared to care...

MEDICAL4 days ago

2-Question Screen Identifies Adolescents at Risk for Future Alcohol Use Disorders

1. The National Institute of Alcohol Abuse and Alcoholism (NIAAA) 2-question screen showed high predictive validity in identifying adolescents at...

MEDICAL4 days ago

MYBPC3 haploinsufficiency results in hypertrophic cardiomyopathy by altering myosin head configurations [PreClinical]

1. Truncating mutations in cardiac myosin-binding protein C (MYBPC3) are a common genetic cause of hypertrophic cardiomyopathy. 2. Haploinsufficiency of...

Advertisement

#CDC

Do you have questions about preventing and managing high #cholesterol? Join @CDCHeart_Stroke and a panel of cholesterol experts for a Facebook Live event on February 25 at 12:30 pm ET. Tune in at facebook.com/millionhearts. #HeartMonth

test Twitter Media - Do you have questions about preventing and managing high #cholesterol? Join @CDCHeart_Stroke and a panel of cholesterol experts for a Facebook Live event on February 25 at 12:30 pm ET. Tune in at https://t.co/rLdeAt7cyx. #HeartMonth https://t.co/6FGXEgv6Wu

HCPs: People with #disabilities are 3 times more likely to have #heartdisease than those without disabilities. In honor of #AmericanHeartMonth, help your patients explore the physical activities suitable for their disability type. bit.ly/2EnsTBx

test Twitter Media - HCPs: People with #disabilities are 3 times more likely to have #heartdisease than those without disabilities. In honor of #AmericanHeartMonth, help your patients explore the physical activities suitable for their disability type. https://t.co/9O33ubwifA https://t.co/SpXpDqLgcP

@Raelove03 CWD and Bovine Spongiform Encephalopathy (BSE, or “Mad Cow Disease”) are both animal prion diseases, a family of rare progressive neurodegenerative disorders. CWD affects deer, elk, reindeer, sika deer and moose, while BSE affects cows.

@Mad_Scientist25 Yes - Chronic Wasting Disease (CWD) is a prion disease that affects deer, elk, reindeer, sika deer and moose. To date, there have been no reported cases of CWD infection in people.

Hunters - be as safe as possible and lower your potential risk of exposure to #ChronicWastingDisease. Take CDC’s recommended steps when hunting in areas with #CWD: bit.ly/2EnQPox.

test Twitter Media - Hunters - be as safe as possible and lower your potential risk of exposure to #ChronicWastingDisease. Take CDC’s recommended steps when hunting in areas with #CWD: https://t.co/aPy5xs4T13. https://t.co/fjxEezzJJt

#lymedisease

@CDC_AMD Hey, can we get more $$$ for research and treatment for #Lymedisease ? Monitoring has done absolutely nothing in regards to testing, treatment, research. It's INSANE that nothing has been done for 40 years about tick borne illnesses.

A negative test does not rule out #LymeDisease Learn more about how to diagnose Lyme here: buff.ly/2sNSHjc

test Twitter Media - A negative test does not rule out #LymeDisease Learn more about how to diagnose Lyme here: https://t.co/OssrqDlLkD https://t.co/4uONqAtSgT

Lyme disease patients (67%) have postponed or avoided medical treatment due to discrimination, disrespect or difficulty obtaining care. #MyLymeData #LymeDisease tinyurl.com/y4rkruvm

test Twitter Media - Lyme disease patients (67%) have postponed or avoided medical treatment due to discrimination, disrespect or difficulty obtaining care. #MyLymeData #LymeDisease https://t.co/Ytok5v5oZl https://t.co/Sfs03xw5Ps

“It gave me a purpose,” she adds of her journey, “and made me find myself all over again.” @AvrilLavigne #LymeDisease #HeadAboveWater people.com/music/avril-la…

#Antiparasitic

Trending

Copyright © 2019. All Rights Reserved. The Human Parasite Support Network.